Skip to content
Biodatica
Start free

Hebei Senlang Biotechnology Inc., Ltd.

Location not on file

OncologyCAR-TPhase II
Compare Sign in to watch

What changed

Phase I trial registered: IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)

7w agoTrial registeredJun 1, 2026Source filing (opens the source filing in a new tab)

Momentum

77no change

Momentum 77 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,727 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    EARLY_PHASE1 registered

    May 25, 2026

    REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS · RECRUITING · sponsor: Peking University People's Hospital · IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)

    ClinicalTrials.gov · NCT07617740 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Nov 28, 2025

    T Lymphoblastic Leukemia/Lymphoma · NOT_YET_RECRUITING · sponsor: Hebei Senlang Biotechnology Inc., Ltd. · Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

    ClinicalTrials.gov · NCT07244380 (opens the source filing in a new tab)

  3. Grant

    R01 · $602k · non-dilutive

    Sep 1, 2024

    UNIVERSITY OF WISCONSIN-MADISON · PI ZHAO, XINYU · NINDS · award ends May 31, 2029 · FMRP regulation of mitochondria and metabolism in mammalian brain development

    NIH RePORTER · NIH RePORTER 11178751 (opens the source filing in a new tab)

  4. Grant

    R01 · $501k · non-dilutive

    Jun 1, 2024

    STATE UNIVERSITY NEW YORK STONY BROOK · PI ZHAO, WEI · NIBIB · award ends Feb 29, 2028 · A direct-indirect dual-layer flat-panel detector for breast cancer detection

    NIH RePORTER · NIH RePORTER 11092178 (opens the source filing in a new tab)

  5. Grant

    R01 · $726k · non-dilutive

    May 1, 2024

    UNIVERSITY OF WISCONSIN-MADISON · PI ZHAO, XINYU · NIMH · award ends Feb 28, 2029 · Interrogate FMRP functions in primate brain development

    NIH RePORTER · NIH RePORTER 11081052 (opens the source filing in a new tab)

  6. Grant

    K99 · $107k · non-dilutive

    Apr 8, 2024

    UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ZHAO, XIAOLEI · NIDCR · award ends Mar 31, 2027 · A signaling crosstalk regulation in neural crest-derived cranial suture

    NIH RePORTER · NIH RePORTER 11077187 (opens the source filing in a new tab)

  7. Grant

    R16 · $142k · non-dilutive

    May 1, 2023

    MOREHOUSE SCHOOL OF MEDICINE · PI ZHAO, XUEYING · NIGMS · award ends Mar 31, 2027 · Molecular mechanisms underlying renal lipotoxicity and DKD progression

    NIH RePORTER · NIH RePORTER 11056875 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources